🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 44 of 173

  1. US 10888609

    CD200 inhibitors and methods of use thereof

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10888581

    Chimeric antigen receptor and methods of use thereof

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10888554

    Salts of heterocyclic modulators of HIF activity for treatment of disease

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10889556

    Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10889538

    Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10889543

    Fine-tune modulators of neuronal excitability for neuropsychiatric disorders

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10889625

    Peptide-based methods for treating neurological injury

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10883117

    Adeno-associated virus variants and methods of use thereof

    Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10881708

    Ang (1-7) derivative oligopeptides for the treatment of pain

    Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10883094

    Transposase polypeptides and uses thereof

    Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10881735

    Phase change nanodroplet conjugates for targeted delivery

    Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10881630

    Creatine oral supplementation using creatine hydrochloride salt

    Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10881720

    Nanoparticles for immune stimulation

    Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10881691

    Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo

    Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10881748

    Nitroxide containing amyloid binding agents for imaging and therapeutic uses

    Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10882903

    Methods and compositions for treating an alphavirus infection

    Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10876118

    Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10875920

    Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10874709

    Conjugate of salicylic acid and peptide

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10874752

    MIBG analogs and uses thereof

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10875912

    EGFL6 specific monoclonal antibodies and methods of their use

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10874727

    Inducible regulatory t-cell generation for hematopoietic transplants

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10874745

    Antimicrobial peptides and methods of treating gram-negative pathogens: polar and non-polar face analogs

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10874719

    Nucleotide phosphate dissipation as a treatment for vascular disorders

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10874643

    5HT agonists for treating disorders

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10875915

    Anti-CXCR5 antibodies and compositions and uses thereof

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10876116

    Anti-ARID3a treatments for inflammatory disorders

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10874631

    Altertoxin II as a selective inhibitor of Ewing family of tumor cells

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10874092

    Humanized skeletal muscle

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10874622

    Dual assembly nanoparticles

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10876134

    Gene therapy for juvenile batten disease

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10874334

    Methods and systems for quantification of blood-brain barrier permeation of glycosylated peptides

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10874678

    Selective high-affinity polydentate ligands and methods of making such

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10878964

    Predictive control model for the artificial pancreas using past predictions

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10869880

    Methods for treating NLRP3 inflammasome-associated diseases, and methods of identifying agents useful therefor

    Expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10869871

    Compositions and methods of modulating short-chain dehydrogenase activity

    Expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10869841

    Nanoscale coatings for encapsulation of biological entities

    Expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10870854

    Inhibitory RNA-based therapeutics targeting ANLN for cancer treatment

    Expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10867702

    Individual and cohort pharmacological phenotype prediction platform

    Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10864270

    Nanostructured carriers for guided and targeted on-demand substance delivery

    Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10864206

    Treatment of neurodegenerative conditions by disruption of Rhes

    Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10864158

    Multilayer thin film drug delivery device and methods of making and using the same

    Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10864168

    Bioactive delivery vehicles

    Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10865403

    Engineered primate cystine/cysteine degrading enzymes for therapeutic uses

    Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10865226

    Peptide showing melanogenesis promoting activity and use thereof

    Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10864222

    Beta-lactamase inhibitors, formulations, and uses thereof

    Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10864153

    Compositions and methods for blocking ultraviolet radiation

    Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10864256

    Methods and compositions for improved cognition

    Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.